Does the media prefer OFIX or LUNG?

In the previous week, Orthofix Medical and Orthofix Medical both had 2 articles in the media. Orthofix Medical's average media sentiment score of 1.77 beat Pulmonx's score of 1.76 indicating that Orthofix Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orthofix Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pulmonx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is LUNG or RCEL more profitable?

Pulmonx has a net margin of -55.03% compared to Avita Medical's net margin of -56.96%. Avita Medical's return on equity of 0.00% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -55.03% -96.66% -38.32% Avita Medical -56.96% N/A -78.53%

Does the media favor LUNG or RCEL?

In the previous week, Avita Medical had 1 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for Avita Medical and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.76 beat Avita Medical's score of 1.62 indicating that Pulmonx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmonx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Avita Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to TMCI or LUNG?

In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 2 articles in the media. Pulmonx's average media sentiment score of 1.76 beat Treace Medical Concepts' score of 1.17 indicating that Pulmonx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Treace Medical Concepts 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulmonx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CV or LUNG more profitable?

Pulmonx has a net margin of -55.03% compared to CapsoVision's net margin of -214.74%. Pulmonx's return on equity of -96.66% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -214.74% -177.85% -135.07% Pulmonx -55.03% -96.66% -38.32%

Is OBIO or LUNG more profitable?

Pulmonx has a net margin of -55.03% compared to Orchestra BioMed's net margin of -184.60%. Pulmonx's return on equity of -96.66% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -184.60% -149.61% -54.15% Pulmonx -55.03% -96.66% -38.32%

Does the media refer more to OBIO or LUNG?

In the previous week, Orchestra BioMed had 9 more articles in the media than Pulmonx. MarketBeat recorded 11 mentions for Orchestra BioMed and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.76 beat Orchestra BioMed's score of 0.99 indicating that Pulmonx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulmonx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Pulmonx (LUNG) Competitors

$1.85 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.88 +0.03 (+1.62%)

As of 09/11/2026 07:30 PM Eastern

Compare

LUNG vs. OFIX, RCEL, TMCI, CV, and OBIO

Should you buy Pulmonx stock or one of its competitors? Pulmonx's main competitors and comparable companies include Orthofix Medical (OFIX), Avita Medical (RCEL), Treace Medical Concepts (TMCI), CapsoVision (CV), and Orchestra BioMed (OBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Pulmonx compare to Orthofix Medical?

Orthofix Medical (NASDAQ:OFIX) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

89.8% of Orthofix Medical shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 2.7% of Orthofix Medical shares are owned by company insiders. Comparatively, 7.5% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Orthofix Medical and Orthofix Medical both had 2 articles in the media. Orthofix Medical's average media sentiment score of 1.77 beat Pulmonx's score of 1.76 indicating that Orthofix Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orthofix Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pulmonx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Orthofix Medical has a net margin of -7.41% compared to Pulmonx's net margin of -55.03%. Orthofix Medical's return on equity of -14.05% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orthofix Medical	-7.41%	-14.05%	-7.17%
Pulmonx	-55.03%	-96.66%	-38.32%

Pulmonx has lower revenue, but higher earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orthofix Medical	$822.31M	0.44	-$92.19M	-$1.54	N/A
Pulmonx	$90.50M	0.88	-$54M	-$1.16	N/A

Orthofix Medical currently has a consensus price target of $14.75, suggesting a potential upside of 65.17%. Pulmonx has a consensus price target of $7.67, suggesting a potential upside of 314.41%. Given Pulmonx's stronger consensus rating and higher probable upside, analysts clearly believe Pulmonx is more favorable than Orthofix Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orthofix Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Orthofix Medical has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Summary

Pulmonx beats Orthofix Medical on 8 of the 14 factors compared between the two stocks.

How does Pulmonx compare to Avita Medical?

Pulmonx (NASDAQ:LUNG) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, Avita Medical had 1 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for Avita Medical and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.76 beat Avita Medical's score of 1.62 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Avita Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pulmonx presently has a consensus price target of $7.67, indicating a potential upside of 314.41%. Avita Medical has a consensus price target of $11.40, indicating a potential upside of 15.38%. Given Pulmonx's higher probable upside, research analysts plainly believe Pulmonx is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Pulmonx has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Avita Medical has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

Pulmonx has a net margin of -55.03% compared to Avita Medical's net margin of -56.96%. Avita Medical's return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-96.66%	-38.32%
Avita Medical	-56.96%	N/A	-78.53%

Avita Medical has lower revenue, but higher earnings than Pulmonx. Avita Medical is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.88	-$54M	-$1.16	N/A
Avita Medical	$71.61M	4.25	-$48.59M	-$1.44	N/A

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Pulmonx beats Avita Medical on 9 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 2 articles in the media. Pulmonx's average media sentiment score of 1.76 beat Treace Medical Concepts' score of 1.17 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Treace Medical Concepts	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulmonx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pulmonx has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69M	1.38	-$59M	-$0.93	N/A
Pulmonx	$90.50M	0.88	-$54M	-$1.16	N/A

Treace Medical Concepts has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by company insiders. Comparatively, 7.5% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Treace Medical Concepts currently has a consensus price target of $5.17, suggesting a potential upside of 14.63%. Pulmonx has a consensus price target of $7.67, suggesting a potential upside of 314.41%. Given Pulmonx's stronger consensus rating and higher probable upside, analysts clearly believe Pulmonx is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Treace Medical Concepts has a net margin of -28.99% compared to Pulmonx's net margin of -55.03%. Treace Medical Concepts' return on equity of -71.37% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-28.99%	-71.37%	-30.49%
Pulmonx	-55.03%	-96.66%	-38.32%

Summary

Treace Medical Concepts beats Pulmonx on 8 of the 15 factors compared between the two stocks.

How does Pulmonx compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

CapsoVision has higher earnings, but lower revenue than Pulmonx. CapsoVision is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	24.38	-$25.32M	-$0.47	N/A
Pulmonx	$90.50M	0.88	-$54M	-$1.16	N/A

In the previous week, Pulmonx had 1 more articles in the media than CapsoVision. MarketBeat recorded 2 mentions for Pulmonx and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.89 beat Pulmonx's score of 1.76 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Very Positive
Pulmonx	Very Positive

91.0% of Pulmonx shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by insiders. Comparatively, 7.5% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CapsoVision has a beta of -2.47, meaning that its stock price is 347% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

CapsoVision currently has a consensus target price of $9.50, suggesting a potential upside of 43.94%. Pulmonx has a consensus target price of $7.67, suggesting a potential upside of 314.41%. Given Pulmonx's stronger consensus rating and higher probable upside, analysts clearly believe Pulmonx is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Pulmonx has a net margin of -55.03% compared to CapsoVision's net margin of -214.74%. Pulmonx's return on equity of -96.66% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
Pulmonx	-55.03%	-96.66%	-38.32%

Summary

Pulmonx beats CapsoVision on 12 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Orchestra BioMed presently has a consensus price target of $13.00, suggesting a potential upside of 112.42%. Pulmonx has a consensus price target of $7.67, suggesting a potential upside of 314.41%. Given Pulmonx's higher possible upside, analysts plainly believe Pulmonx is more favorable than Orchestra BioMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Orchestra BioMed had 9 more articles in the media than Pulmonx. MarketBeat recorded 11 mentions for Orchestra BioMed and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.76 beat Orchestra BioMed's score of 0.99 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulmonx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Orchestra BioMed has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Comparatively, 7.5% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Orchestra BioMed has higher earnings, but lower revenue than Pulmonx. Orchestra BioMed is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	10.99	-$52.70M	-$0.85	N/A
Pulmonx	$90.50M	0.88	-$54M	-$1.16	N/A

Pulmonx has a net margin of -55.03% compared to Orchestra BioMed's net margin of -184.60%. Pulmonx's return on equity of -96.66% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-184.60%	-149.61%	-54.15%
Pulmonx	-55.03%	-96.66%	-38.32%

Summary

Pulmonx beats Orchestra BioMed on 8 of the 15 factors compared between the two stocks.

Get Pulmonx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUNG vs. The Competition

Export

Metric	Pulmonx	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$79.45M	$5.48B	$7.16B	$12.85B
Dividend Yield	N/A	1.80%	2.57%	11.17%
P/E Ratio	-1.59	25.09	274.94	25.36
Price / Sales	0.88	71.54	686.57	116.78
Price / Cash	N/A	32.57	76.65	51.52
Price / Book	1.41	5.97	10.33	6.20
Net Income	-$54M	$150.75M	$3.50B	$358.50M
7 Day Performance	-16.29%	-2.83%	-3.32%	-2.35%
1 Month Performance	-14.35%	-3.73%	-0.53%	-3.23%
1 Year Performance	8.82%	9.38%	23.51%	8.79%

Pulmonx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUNG Pulmonx	3.5013 of 5 stars	$1.85 flat	$7.67 +314.4%	+8.8%	$79.45M	$90.50M	N/A	250	Positive News Gap Up
OFIX Orthofix Medical	3.1433 of 5 stars	$9.06 -2.5%	$14.75 +62.8%	-40.1%	$374.11M	$822.31M	N/A	1,605	Analyst Upgrade
RCEL Avita Medical	2.1631 of 5 stars	$10.79 -3.6%	$11.40 +5.6%	+116.7%	$327.96M	$71.61M	N/A	130	Positive News
TMCI Treace Medical Concepts	2.8989 of 5 stars	$4.76 -1.1%	$5.17 +8.6%	-37.5%	$311.93M	$212.69M	N/A	250	Positive News Gap Up
CV CapsoVision	3.1374 of 5 stars	$6.15 +2.7%	$9.50 +54.5%	+60.2%	$307.81M	$13.55M	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUNG) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmonx (LUNG) Competitors

LUNG vs. OFIX, RCEL, TMCI, CV, and OBIO

How does Pulmonx compare to Orthofix Medical?

Summary

How does Pulmonx compare to Avita Medical?

Summary

How does Pulmonx compare to Treace Medical Concepts?

Summary

How does Pulmonx compare to CapsoVision?

Summary

How does Pulmonx compare to Orchestra BioMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmonx (LUNG) Competitors

LUNG vs. OFIX, RCEL, TMCI, CV, and OBIO

How does Pulmonx compare to Orthofix Medical?

Do insiders & institutionals have more ownership in OFIX or LUNG?

Does the media prefer OFIX or LUNG?

Is OFIX or LUNG more profitable?

Which has stronger earnings and valuation, OFIX or LUNG?

Do analysts prefer OFIX or LUNG?

Which has more risk & volatility, OFIX or LUNG?

Summary

How does Pulmonx compare to Avita Medical?

Does the media favor LUNG or RCEL?

Do analysts prefer LUNG or RCEL?

Which has more risk & volatility, LUNG or RCEL?

Is LUNG or RCEL more profitable?

Which has higher valuation & earnings, LUNG or RCEL?

Do institutionals and insiders believe in LUNG or RCEL?

Summary

How does Pulmonx compare to Treace Medical Concepts?

Does the media refer more to TMCI or LUNG?

Which has better valuation and earnings, TMCI or LUNG?

Which has more risk & volatility, TMCI or LUNG?

Do institutionals & insiders hold more shares of TMCI or LUNG?

Do analysts recommend TMCI or LUNG?

Is TMCI or LUNG more profitable?

Summary

How does Pulmonx compare to CapsoVision?

Which has better earnings and valuation, CV or LUNG?

Does the media refer more to CV or LUNG?

Do institutionals and insiders hold more shares of CV or LUNG?

Which has more volatility and risk, CV or LUNG?

Do analysts prefer CV or LUNG?

Is CV or LUNG more profitable?

Summary

How does Pulmonx compare to Orchestra BioMed?

Do analysts prefer OBIO or LUNG?

Does the media refer more to OBIO or LUNG?

Which has more volatility & risk, OBIO or LUNG?

Do insiders and institutionals hold more shares of OBIO or LUNG?

Which has higher valuation and earnings, OBIO or LUNG?

Is OBIO or LUNG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools